구조모아 (StructureMoa)항암 chemical structure spider web
방문프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | enfortumab vedotin (Padcev, ASG-22ME, enfortumab-vedotin-ejfv) Astellas / Pfizer (Seagen)·Nectin-4 201 trials·t½ ADC ~3.4 days; free MMAE ~2.4 days | nadofaragene firadenovec (Adstiladrin, rAd-IFNα/Syn3, nadofaragene firadenovec-vncg) Ferring Pharmaceuticals·IFNα2b (adenoviral) 10 trials | ||
|---|---|---|---|---|
Overview Program | Tecentriq (atezolizumab) | Padcev (enfortumab vedotin) | Disitamab Vedotin (RC48) | Adstiladrin (nadofaragene firadenovec) |
Overview Company | Roche / Genentech | Astellas / Pfizer (Seagen) | RemeGen | Ferring Pharmaceuticals |
Overview Modality | ANTIBODY | ADC | ADC | CGT |
Overview Target | PD-L1 | Nectin-4 | HER2 | IFNα2b (adenoviral) |
Overview Indication | NSCLC, SCLC, HCC, TNBC, urothelial carcinoma, and others | Locally advanced or metastatic urothelial carcinoma | HER2+ urothelial, gastric, breast | High-risk BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) |
Overview Phase | APPROVED | APPROVED | APPROVED | APPROVED |
Overview Status | APPROVED | APPROVED | ACTIVE | APPROVED |
Overview Content status | Curated Core | Curated Core | Curated Core | Curated Core |
Overview Data Confidence | Data Confidence · High | Data Confidence · High | Data Confidence · High | Data Confidence · High |
Overview Development Signal | Development Signal · Established | Development Signal · Established | Development Signal · Established | Development Signal · Established |
Overview Approval status | FDA approved | FDA approved | FDA approved | FDA approved |
Positioning Key differentiator | novel agents have been approved in recent years (including systemic pembrolizumab, nogapendekin alfa inbakicept-pmln, N-803), | Nectin-4 is near-uniformly expressed in urothelial carcinoma, giving an unusually clean tumor-selective target in that tissue. | Novel anti-HER2 mAb with distinct epitope | Local bladder gene delivery avoiding systemic AAV exposure |
Positioning Known limitation | resistance to existing therapies | Nectin-4 loss, MMAE efflux, and tubulin alterations. | resistance mechanisms, optimize payload delivery, and minimize off-target toxicity | downregulation of mTOR and STAT3 at the single-cell resolution, both in vitro and in vivo |
Positioning Development positioning | — | 1L standard of care in urothelial carcinoma with pembrolizumab. | Lower ILD signal vs DXd in some datasets | Gene therapy option vs pembrolizumab / radical cystectomy |
Technology Payload | — | MMAE (monomethyl auristatin E, tubulin inhibitor) | MMAE | — |
Technology Linker | — | Protease-cleavable mc-vc-PAB, DAR ~3.8 | Cleavable | — |
Technology DAR | — | DAR 3.8 | — | — |
Technology Vector | — | — | — | rAd-IFNα/Syn3 |
MoA Mechanism | Atezolizumab binds PD-L1 and blocks its interaction with PD-1 and B7.1 (CD80), enabling restoration of antitumor T-cell responses without direct PD-1 engagement on T cells. | Binds Nectin-4 on urothelial tumor cells, internalizes, and releases MMAE after cathepsin B cleavage; microtubule disruption arrests mitosis and triggers apoptosis. | Disitamab vedotin binds a distinct HER2 epitope (different from trastuzumab), internalizes, and releases MMAE via cleavable linker, causing microtubule disruption and apoptosis. | Nadofaragene firadenovec is a non-replicating adenoviral vector delivering IFNα2b cDNA to bladder urothelium for BCG-unresponsive NMIBC. |
MoA Biomarker | PD-L1 IC/TC scoring in NSCLC and UC; tumor-type-specific thresholds. | Nectin-4 expression is high in urothelial carcinoma; no companion diagnostic required. | HER2 expression (IHC); activity in HER2+ urothelial and gastric cancers. | Complete response at 3/6/12 months (cystoscopy, cytology, biopsy). |
PK/PD Half-life | 27 h | ADC ~3.4 days; free MMAE ~2.4 days | ~5 days (ADC, clinical PK) | — |
PK/PD Species | Mouse, Human | Cynomolgus monkey, ORR, PFS, OS | Mouse, ORR in HER2+ UC/gastric | Mouse |
PK/PD Animal (cat.) | Human, Mouse | Human, NHP, In vitro | Human, Mouse, In vitro | Mouse |
PK/PD Experiment | PD | Pharmacokinetic | pd | pharmacodynamic |
Toxicology Species | Cynomolgus monkey, Mouse, Human | Cynomolgus monkey, Mouse, Rat | Cynomolgus monkey, Mouse | Cynomolgus monkey, Mouse |
Toxicology Animal (cat.) | — | — | NHP | — |
Toxicology Major finding | Immune-mediated pneumonitis, hepatitis, colitis, endocrinopathies. | Boxed warning for serious skin reactions including SJS/TEN. Hyperglycemia, peripheral neuropathy, ocular surface toxicity, and pneumonitis also require monitoring. | Hematologic toxicity and peripheral neuropathy class effects of MMAE; ILD reported at lower frequency than DXd ADCs in published datasets. | Instillation-site reactions, bladder spasm, micturition urgency; systemic IFN effects uncommon. |
Toxicology CRS | N/A | N/A | N/A | N/A |
Clinical Safety signal | Immune-mediated pneumonitis, hepatitis, colitis, endocrinopathies. | Boxed warning for serious skin reactions including SJS/TEN. Hyperglycemia, peripheral neuropathy, ocular surface toxicity, and pneumonitis also require monitoring. | Hematologic toxicity and peripheral neuropathy class effects of MMAE; ILD reported at lower frequency than DXd ADCs in published datasets. | Instillation-site reactions, bladder spasm, micturition urgency; systemic IFN effects uncommon. |
Clinical Selected reported efficacy | — | ORR 67.7% | — | ORR 55% |
Clinical Reported ORR | — | 67.7% (EV + pembrolizumab) | — | 55% |
Clinical Reported PFS | 1.7 | 12.5 mo vs 6.3 mo (chemo) | — | — |
Clinical Reported OS | 7.6 | 31.5 mo vs 16.1 mo (chemo) | — | 100 |
Clinical Result source | ClinicalTrials.gov NCT04457778 | EV-302 / KEYNOTE-A39 (NCT04223856) | — | ClinicalTrials.gov NCT02773849 |
Clinical Program phase | APPROVED | APPROVED | APPROVED | APPROVED |
Clinical Trial activity | No active/completed counts | No active/completed counts | No active/completed counts | 6 recruiting · 3 completed |
Clinical Trial ref | NCT04457778 | NCT04223856 | — | NCT02773849 |
Preclinical Animal (cat.) | Mouse | Human, Mouse, In vitro | — | Mouse, In vitro |
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | enfortumab vedotin (Padcev, ASG-22ME, enfortumab-vedotin-ejfv) Astellas / Pfizer (Seagen)·Nectin-4 201 trials·t½ ADC ~3.4 days; free MMAE ~2.4 days | nadofaragene firadenovec (Adstiladrin, rAd-IFNα/Syn3, nadofaragene firadenovec-vncg) Ferring Pharmaceuticals·IFNα2b (adenoviral) 10 trials | ||
|---|---|---|---|---|
Overview Program | Tecentriq (atezolizumab) | Padcev (enfortumab vedotin) | Disitamab Vedotin (RC48) | Adstiladrin (nadofaragene firadenovec) |
Overview Company | Roche / Genentech | Astellas / Pfizer (Seagen) | RemeGen | Ferring Pharmaceuticals |
Overview Modality | ANTIBODY | ADC | ADC | CGT |
Overview Target | PD-L1 | Nectin-4 | HER2 | IFNα2b (adenoviral) |
Overview Indication | NSCLC, SCLC, HCC, TNBC, urothelial carcinoma, and others | Locally advanced or metastatic urothelial carcinoma | HER2+ urothelial, gastric, breast | High-risk BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) |
Overview Phase | APPROVED | APPROVED | APPROVED | APPROVED |
Overview Status | APPROVED | APPROVED | ACTIVE | APPROVED |
Overview Content status | Curated Core | Curated Core | Curated Core | Curated Core |
Overview Data Confidence | Data Confidence · High | Data Confidence · High | Data Confidence · High | Data Confidence · High |
Overview Development Signal | Development Signal · Established | Development Signal · Established | Development Signal · Established | Development Signal · Established |
Overview Approval status | FDA approved | FDA approved | FDA approved | FDA approved |
Positioning Key differentiator | novel agents have been approved in recent years (including systemic pembrolizumab, nogapendekin alfa inbakicept-pmln, N-803), | Nectin-4 is near-uniformly expressed in urothelial carcinoma, giving an unusually clean tumor-selective target in that tissue. | Novel anti-HER2 mAb with distinct epitope | Local bladder gene delivery avoiding systemic AAV exposure |
Positioning Known limitation | resistance to existing therapies | Nectin-4 loss, MMAE efflux, and tubulin alterations. | resistance mechanisms, optimize payload delivery, and minimize off-target toxicity | downregulation of mTOR and STAT3 at the single-cell resolution, both in vitro and in vivo |
Positioning Development positioning | — | 1L standard of care in urothelial carcinoma with pembrolizumab. | Lower ILD signal vs DXd in some datasets | Gene therapy option vs pembrolizumab / radical cystectomy |
Technology Payload | — | MMAE (monomethyl auristatin E, tubulin inhibitor) | MMAE | — |
Technology Linker | — | Protease-cleavable mc-vc-PAB, DAR ~3.8 | Cleavable | — |
Technology DAR | — | DAR 3.8 | — | — |
Technology Vector | — | — | — | rAd-IFNα/Syn3 |
MoA Mechanism | Atezolizumab binds PD-L1 and blocks its interaction with PD-1 and B7.1 (CD80), enabling restoration of antitumor T-cell responses without direct PD-1 engagement on T cells. | Binds Nectin-4 on urothelial tumor cells, internalizes, and releases MMAE after cathepsin B cleavage; microtubule disruption arrests mitosis and triggers apoptosis. | Disitamab vedotin binds a distinct HER2 epitope (different from trastuzumab), internalizes, and releases MMAE via cleavable linker, causing microtubule disruption and apoptosis. | Nadofaragene firadenovec is a non-replicating adenoviral vector delivering IFNα2b cDNA to bladder urothelium for BCG-unresponsive NMIBC. |
MoA Biomarker | PD-L1 IC/TC scoring in NSCLC and UC; tumor-type-specific thresholds. | Nectin-4 expression is high in urothelial carcinoma; no companion diagnostic required. | HER2 expression (IHC); activity in HER2+ urothelial and gastric cancers. | Complete response at 3/6/12 months (cystoscopy, cytology, biopsy). |
PK/PD Half-life | 27 h | ADC ~3.4 days; free MMAE ~2.4 days | ~5 days (ADC, clinical PK) | — |
PK/PD Species | Mouse, Human | Cynomolgus monkey, ORR, PFS, OS | Mouse, ORR in HER2+ UC/gastric | Mouse |
PK/PD Animal (cat.) | Human, Mouse | Human, NHP, In vitro | Human, Mouse, In vitro | Mouse |
PK/PD Experiment | PD | Pharmacokinetic | pd | pharmacodynamic |
Toxicology Species | Cynomolgus monkey, Mouse, Human | Cynomolgus monkey, Mouse, Rat | Cynomolgus monkey, Mouse | Cynomolgus monkey, Mouse |
Toxicology Animal (cat.) | — | — | NHP | — |
Toxicology Major finding | Immune-mediated pneumonitis, hepatitis, colitis, endocrinopathies. | Boxed warning for serious skin reactions including SJS/TEN. Hyperglycemia, peripheral neuropathy, ocular surface toxicity, and pneumonitis also require monitoring. | Hematologic toxicity and peripheral neuropathy class effects of MMAE; ILD reported at lower frequency than DXd ADCs in published datasets. | Instillation-site reactions, bladder spasm, micturition urgency; systemic IFN effects uncommon. |
Toxicology CRS | N/A | N/A | N/A | N/A |
Clinical Safety signal | Immune-mediated pneumonitis, hepatitis, colitis, endocrinopathies. | Boxed warning for serious skin reactions including SJS/TEN. Hyperglycemia, peripheral neuropathy, ocular surface toxicity, and pneumonitis also require monitoring. | Hematologic toxicity and peripheral neuropathy class effects of MMAE; ILD reported at lower frequency than DXd ADCs in published datasets. | Instillation-site reactions, bladder spasm, micturition urgency; systemic IFN effects uncommon. |
Clinical Selected reported efficacy | — | ORR 67.7% | — | ORR 55% |
Clinical Reported ORR | — | 67.7% (EV + pembrolizumab) | — | 55% |
Clinical Reported PFS | 1.7 | 12.5 mo vs 6.3 mo (chemo) | — | — |
Clinical Reported OS | 7.6 | 31.5 mo vs 16.1 mo (chemo) | — | 100 |
Clinical Result source | ClinicalTrials.gov NCT04457778 | EV-302 / KEYNOTE-A39 (NCT04223856) | — | ClinicalTrials.gov NCT02773849 |
Clinical Program phase | APPROVED | APPROVED | APPROVED | APPROVED |
Clinical Trial activity | No active/completed counts | No active/completed counts | No active/completed counts | 6 recruiting · 3 completed |
Clinical Trial ref | NCT04457778 | NCT04223856 | — | NCT02773849 |
Preclinical Animal (cat.) | Mouse | Human, Mouse, In vitro | — | Mouse, In vitro |
추천 비교
추천 비교